Elizabeth Dale, MD
Ophthalmology · Bala Cynwyd, PANPI 1811218332
Payments from drug & device makers
Across 115 payments — averaging $234.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$24K
- AbbVie$709
- Alcon$528
- Glaukos Corporation$413
- NEW World Medical,inc.$227
- Aerie Pharmaceuticals, Inc.$143
- plus $633 from 15 others
What the payments were for
- Speaking & faculty fees$21,10078%
- Travel & lodging$1,4936%
- Food & beverage$4,30316%
- Gifts$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 38 | $24,306 |
| AbbVie(2 entities) | 21 | $709 |
| Alcon | 9 | $528 |
| Glaukos Corporation | 4 | $413 |
| NEW World Medical,inc. | 5 | $227 |
| Aerie Pharmaceuticals, Inc. | 7 | $143 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $117 |
| Dompe US, Inc. | 5 | $85 |
| Biotissue Holdings Inc. | 3 | $66 |
| Bausch & Lomb Americas Inc. | 3 | $58 |
| Novartis | 4 | $57 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $44 |
| Thea Pharma Inc. | 3 | $41 |
| Tarsus Pharmaceuticals, Inc. | 2 | $38 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Amgen | 1 | $22 |
| Harrow Eye, LLC | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
| Iridex Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$23,658
- SION SURGICAL INSTRUMENT$11,709
- iDoseTR$184
- Hydrus Microstent$132
- Tecnis IOL$117
- Clareon$115
- OMNI$106
How this compares
$26,958 in reported general payments places this provider in the 85th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 509 | $225,116 |
| RhopressaNetarsudil Mesylate | 160 | $77,344 |
| Alphagan PBrimonidine Tartrate | 216 | $59,554 |
| Brimonidine Tartrate | 1,052 | $58,697 |
| CombiganBrimonidine Tartrate/Timolol | 193 | $56,612 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 119 | $31,359 |
| RestasisCyclosporine | 23 | $29,899 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 174 | $29,529 |
| Travoprost | 177 | $29,420 |
| VyzultaLatanoprostene Bunod | 76 | $27,924 |
| RocklatanNetarsudil Mesylat/Latanoprost | 55 | $21,639 |
| Prednisolone Acetate | 646 | $21,423 |
| Latanoprost | 1,943 | $19,701 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,027 | $17,591 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 66 | $14,791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan, Restasis | $709 | $371,181941 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $143 | $98,983215 claims |
| AlconSimbrinza | $528 | $31,359119 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $58 | $27,92476 claims |
| NovartisTravatan Z | $57 | $8,66124 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $44 | $4,89722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Bala Cynwyd
- Brandon AyresBala Cynwyd$1.3M
- Tina XiaBala Cynwyd$134K
- Richard TippermanBala Cynwyd$111K
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.